Date Title and Summary Additional Formats
Sep 21, 2023
PHAXIAM Provides Business and Financial Update For the First Half of 2023
Sep 19, 2023
PHAXIAM Therapeutics extends its phage portfolio to Klebsiella pneumoniae, a new resistant and aggressive bacterial target
Sep 18, 2023
PHAXIAM Therapeutics announces the completion of its reverse share split
Sep 08, 2023
Monthly information related to total number of voting rights and shares composing the share capital _August 31, 2023
Sep 05, 2023
PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences
Aug 08, 2023
Monthly information related to total number of voting rights and shares composing the share capital _July 31, 2023
Jul 27, 2023
PHAXIAM Therapeutics announces a reverse share split of its shares
Jun 28, 2023
Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM
Jun 27, 2023
Monthly information related to total number of voting rights and shares composing the share capital - June 26, 2023
Jun 26, 2023
ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics